HORNBILL: A First-in-Human Phase I/IIa Study of the Safety, Tolerability, and Early Pharmacodynamics of BI 764524 for Diabetic Macular Ischemia

Objective: To report safety and early pharmacodynamic results from a first-in-human trial of intravitreal (IVT) anti-semaphorin 3A antibody in participants with diabetic macular ischemia (DMI). Design: HORNBILL, a phase I/IIa study of BI 764524, comprised a nonrandomized, open-label, uncontrolled, s...

Full description

Bibliographic Details

Published in:	Ophthalmology Science
Main Authors:	Quan Dong Nguyen, MD, MSc, Chirag Jhaveri, MD, Maged Habib, MD, Yasir J. Sepah, MBBS, Khaled Nassar, MD, PhD, Bartlomiej Krawczyk, PhD, Gudrun Simons, PhD, Andrea Giani, MD, Elizabeth Pearce, PhD, Martin Gliem, MD, Mohamed Ahmed, MBBCh, MD, Sobha Sivaprasad, DM
Format:	Article
Language:	English
Published:	Elsevier 2025-09-01
Subjects:	Diabetic retinopathy Sema3A First-in-human Retinal nonperfusion Ischemia
Online Access:	http://www.sciencedirect.com/science/article/pii/S266691452500079X